The Cidofovir Controversy

  • Griffin D. Santarelli
  • Craig S. Derkay


Recurrent respiratory papillomatosis (RRP) is a disease of viral etiology and is caused by the human papilloma virus (HPV). Although it is a benign disease process, there are very serious sequelae because of its involvement in the tracheobronchial tree. Multiple treatment modalities have emerged to control aerodigestive tract proliferation, ranging from surgery to immunomodulating medications, including antiviral drugs such as cidofovir. Cidofovir is an adjunct therapy employed as an intralesional injection. While cidofovir has historically been employed without long-term consequences, there are concerns associated with its use as a papilloma treatment, including potential malignant transformation of lesions, renal failure, and neutropenia. This chapter will focus on the benefits and risks of employing cidofovir in the RRP patient population as well as suggested treatment algorithms. A summary table of clinical reports of other adjuvant therapies is provided as an appendix at the end of the chapter.


Recurrent respiratory papillomatosis (RRP) Cidofovir Human papilloma virus (HPV) 


  1. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon α-2b. Eur Respir J. 2001;17:830–1.CrossRefPubMedGoogle Scholar
  2. Avramov T, Vetckova E, Nikolova M, Valev D, Manolova A, Tafradgiiska M, Kostadinov D, Tchalacov I. Therapeutic approaches to the treatment of recurrent respiratory papillomatosis of the aerodigestive tract (a clinical study). Biotechnol Biotechnol Equip. 2014;28(4):668–73.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Beaumanis MM, Elmaraghy CA. Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: a case report. Int J Pediatr Otorhinolaryngol. 2016;91:166–9.CrossRefGoogle Scholar
  4. Broekema F, Dikkers F. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008;265(8):871–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. CDC. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. 2015.Google Scholar
  6. Chadha NK, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis [review]. Cochrane Database Syst Rev. 2010;1:cd005053.Google Scholar
  7. Chaturvedi J, Sreenivas V, Hemanth V, Nandakumar R. Management of adult recurrent respiratory papillomatosis with oral acyclovir following micro laryngeal surgery: a case series. Indian J Otolaryngol Head Neck Surg. 2014;66(Suppl 1):S359–63.CrossRefGoogle Scholar
  8. Chhetri DK, Blumin JH, Shapiro NL, Berke GS. Office based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Head Neck Surg. 2002;26:642–8.CrossRefGoogle Scholar
  9. Chirila M, Bolboaca SD. Cllinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271(5):1135–42.CrossRefPubMedGoogle Scholar
  10. Connor MP, et al. Effect of vocal fold injection of cidofovir and bevacizumab in a porcine model. JAMA Otolaryngol Head Neck Surg. 2014;140(2):155–9.CrossRefPubMedGoogle Scholar
  11. Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR. HspE7 treatment of pediatric respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol. 2005;114(9):730–7.CrossRefPubMedGoogle Scholar
  12. Derkay C, Volsky P, Rosen C. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope. 2013;123:705–12.CrossRefPubMedGoogle Scholar
  13. Dickens P. Human papillomavirus 6, 11, and 16 in laryngeal Papillomas. J Pathol. 1991a;165:243–6.CrossRefPubMedGoogle Scholar
  14. Dickens P. Human papillomavirus 6, 11, and 16 in laryngeal Papillomas. J Pathol. 1991b;165:243–6.CrossRefPubMedGoogle Scholar
  15. FDA Regulatory Information. “Off-label” and investigational use of marketed drugs, biologics, and medical devices - information sheet, 25 Jan 2016, .
  16. Food and Drug Administration. FDA Approves Cidofovir for AIDS-Related Retinitis, 1996.,
  17. Gilead Sciences. Cidofovir Injection Safety Data Sheet, n.d..,
  18. Ginsburg G, Willard H. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–87.CrossRefPubMedGoogle Scholar
  19. Grasso M, Remacle M, Bachy V, Van Der Vorst S, Lawson G. Use of cidofovir in HPV patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271:2983–90.CrossRefPubMedGoogle Scholar
  20. Gron AL. Malignant degeneration in laryngeal Papillomatosis. Ugeskr Laeger. 2011;173:5067.Google Scholar
  21. Hall J, Chen K, Yoo M, et al. Natural progression of dysplasia in adult recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 2011;144(2):252–6.CrossRefPubMedGoogle Scholar
  22. Hawkes M, Campisi P, Zafar R, et al. Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J. 2008;27:149–54.CrossRefPubMedGoogle Scholar
  23. Hermann JS, Weckx LY, Monteiro Nurmberger J, Santos Junior GF, Campos Pignatari AC, Nagata Pignatari SS. Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94–8.CrossRefPubMedGoogle Scholar
  24. Hyung-Tae K, Baizhumanova A. Is recurrent respiratory Papillomatosis a manageable or curable disease? Laryngoscope. 2016 Jun;126(6):1359–64.CrossRefGoogle Scholar
  25. Jeong WJ, Park SW, Shin M. Presence of HPV type 6 in dysplasia and carcinoma arising from recurrent respiratory Papillomatosis. Head Neck. 2009;31:1095–101.CrossRefPubMedGoogle Scholar
  26. Karatayli-Ozgursoy S, Bishop J, Hillel A, Akst L, Best S. Risk factors for dysplasia in recurrent respiratory Papillomatosis in an adult and pediatric population, annals of otology. Rhinol Laryngol. 2016;125(3):235–41.CrossRefGoogle Scholar
  27. Ksiazek J, Prager J, Sun G, Wood R, Arjmand E. Inhaled cidofovir as an adjuvant therapy for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 2011;144(4):639–41.CrossRefPubMedGoogle Scholar
  28. Lawrie TA, Nordin A, Chakrabarti M, Bryant A, Kaushik S, Pepas L. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2016;1 doi: 10.1002/14651858.CD011837.pub2.
  29. Lei J, Yu W, Yuexin L, Qi C, Xiumin S, Tianyu Z. Topical measles-mumps-rubella vaccine in the treatment of recurrent respiratory papillomatosis: results of a preliminary randomized, controlled trial. Ear Nose Throat J. 2012;91(4):174–5.PubMedGoogle Scholar
  30. Lindsay F, Bloom D, Pransky S, et al. Histologic review of Cidofovir-treated recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2008;117:113–7.Google Scholar
  31. McMurray J, Connor N, Ford C. Cidofovir efficacy in recurrent respiratory Papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol. 2008;117(7):477–83.CrossRefPubMedGoogle Scholar
  32. Meacham RK, Thompson JW. Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. Ear Nose Throat J. 2017;96(2):69–74.PubMedGoogle Scholar
  33. Mohr M, Schliemann C, Biermann C, Schmidt L, Kessler T, Schmidt J, Wiebe K, Muller K, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett. 2014;8:1912–8.PubMedPubMedCentralGoogle Scholar
  34. Nodarse-Cuni H, Iznaga-Marin N, Viera-Alvarez D, Rodriguez-Gomez H, Fernandez-Fernandez H, Blanco-Lopez Y, Viada-Gonzalez C, Lopez-Saura P. Cuban Group for the Study of Interferon in Recurrent Respiratory Papillomatosis. Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report). J Laryngol Otol. 2004;118(9):681–7.CrossRefPubMedGoogle Scholar
  35. Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope. 2003;113:1583–7.CrossRefPubMedGoogle Scholar
  36. Pransky SM, Brewster DF, Magit AE, Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000;126:1239–43.CrossRefPubMedGoogle Scholar
  37. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg. 1999;125:1143–8.CrossRefPubMedGoogle Scholar
  38. Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg. 2013;139(5):496–501.CrossRefPubMedGoogle Scholar
  39. Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice. 2004;18(2):248–53.CrossRefPubMedGoogle Scholar
  40. Segarra-Newnham M, Vodolo KM. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001;35(6):741–4.CrossRefPubMedGoogle Scholar
  41. Shehab N, Burgunda VS, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy. 2005;25:977–89.CrossRefPubMedGoogle Scholar
  42. Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214–21.CrossRefPubMedGoogle Scholar
  43. Snoeck R, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol. 1998;54:219–25.CrossRefPubMedGoogle Scholar
  44. Suter-Montano T, Montano E, Martinez C, Plascencia T, Sepulveda MT, Rodriguez M. Adult recurrent respiratory papillomatosis: a new therapeutic approach with pegylated interferon alpha 2a (Peg-IFNα-2a) and GM-CSF. Otolaryngol Head Neck Surg. 2013;148(2):253–60.CrossRefPubMedGoogle Scholar
  45. Tjon Pian R, et al. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol. 2013;270:1679–87.CrossRefGoogle Scholar
  46. Van Cutsem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol. 1995;45:230–5.CrossRefPubMedGoogle Scholar
  47. Vats A, Shapiro R, Singh R. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation. 2003;75:105–12.CrossRefPubMedGoogle Scholar
  48. Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJ. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114:836–9.CrossRefPubMedGoogle Scholar
  49. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues — a survey. Antivir Res. 2001;49:55–74.CrossRefPubMedGoogle Scholar
  50. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice. 2015;29(2):223–9.CrossRefPubMedGoogle Scholar
  51. Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, Freeman MW, Halvorsen YD, Hillman RE. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Otolaryngology, Head and Neck SurgeryEastern Virginia Medical SchoolNorfolkUSA

Personalised recommendations